Absorb GT1 Bioresorbable Vascular Scaffold made by Abbot Vascular gained FDA Approval in July of 2016 subsequent to Premarket Approval Application (PMA: P150023)
Intended Use: The Absorb GT1 Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
To Learn More About the Emerging Absorb GT1 Bioresorbable Vascular Scaffold Potential Litigation:
The emerging GT1 Bioresorbable Vascular Scaffold Potential Litigation will be used as a case study in the May 18th to 21st 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” To register for the May Couse, contact Jenny Levine at email@example.com or call (954) 520-4494.
For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”
Course attendees will receive the benefit of a step by step analysis of the emerging GT1 Bioresorbable Vascular Scaffold Potential using these primary metrics:
Some of the top mass tort trial lawyers in the country have endorsed the Mass Tort Nexus Immersion Course, including Annesley DeGaris>
The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively. Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.